medigraphic.com
SPANISH

Revista Médica Electrónica

ISSN 1684-1824 (Electronic)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2014, Number 4

<< Back Next >>

Rev Méd Electrón 2014; 36 (4)

Experiences in conducting clinical trials in the province of Matanzas. 2005-2012

Negret HM, Naranjo RS, Cárdenas GD, Ramos CG
Full text How to cite this article

Language: Spanish
References: 13
Page: 417-424
PDF size: 44.83 Kb.


Key words:

clinical trial, included patients, promoting centers.

ABSTRACT

Clinical trial is a methodology suitable to evaluate a therapeutic intervention in human beings, commonly known as the golden standard In the decade of the 90es, the province of Matanzas was inserted in the clinical trial national net, and there have being evaluated ample impact products in coordination with the Clinical Trial National Coordinating Center (CENCEC, in Spanish). We developed a retrospective descriptive study with the aim of evaluating the social impact of the clinical trials in the province of Matanzas during the period 2005-2012. In the analyzed period there were finished 11 clinical trials and there are 24 more in course; there are a total of 11 evaluated products. The total number of clinical sites-clinical trial is 9, participating 196 researchers, and 443 patients through the period. The promoting centers with more participation are: the Center of Molecular Inmunology, the National Center of Farming Health, the Ozone Technical Office and the Center of Genetic Engineering and Biotechnologies. The drugs evaluated in the clinical trials were against the following diseases: cancer, respiratory distress, bronchial asthma and predialysis. Most of the products evaluated in national clinical trials are indicated against cancer, and its most representative location is the lungs; other locations are prostate glands, esophagus, kidneys and mammas. The positive influence in the National Health System is expressed in benefits like improvement in health indicators, changes in the medical care patterns of the disease in which the product was evaluated, and formation and improvement of the human resources participating in the trial.


REFERENCES

  1. Pascual MA, Jiménez Rivero G, Fors M, López I, Rodríguez O, Torres A, et al. La organización de los ensayos clínicos en Cuba: influencia en el desarrollo de los productos de la Industria Médico-Farmacéutica y Biotecnológica y en el Sistema de Salud de Cuba. Premio Anual de la Salud, Concurso Nacional. Enero; 2010.

  2. Pascual López MA, Jiménez Rivero G, Torres Pombert A, Fors López MM, López Zayas I. Surgimiento, evolución y principales resultados del Centro Nacional Coordinador de Ensayos Clínicos. Rev Cubana Farm [Internet]. 2011 [citado 14 Abr 2014];45(1). Disponible en: http://scielo.sld.cu/scielo.php?pid=S0034- 75152011000100002&script=sci_arttext

  3. Karanicolas PJ, Montori VM, Devereaux PJ, Schünemann H, Guyatt GH. A new "mechanistic-practical" framework for designing and interpreting randomized trials. J Clin Epidemiol. 2009;62(5):479-84. Citado en PubMed; PMID: 18468856.

  4. Perdomo Leyva D, Herrero Aguirre H, Landazuri Llago S, Griñan Semanat D, Peacok Aldana S. Experiencia en la ejecución de ensayos clínicos multicéntricos en Santiago de Cuba durante 15 años. Medisan [Internet]. 2010 [citado 14 Abr 2014];14(1). Disponible en: http://scielo.sld.cu/scielo.php?pid=S1029- 30192010000100018&script=sci_arttext&tlng=pt

  5. Negret Hernández M, Naranjo Rodríguez S, Ponce Santoyo M, Pineda Cruz A, Vichot Fernández L. La calidad en el diseño del ensayo clínico en la Medicina Tradicional Natural. Rev Méd Electrón [Internet]. 2012 May-Jun [citado 5 Ene 2014];34(3). Disponible en: http://www.revmatanzas.sld.cu/revista%20medica/ano%202012/vol3%202012/te ma09.htm

  6. Laporte JR. Principios básicos de investigación clínica. Madrid: Ergon, SA; 1993.

  7. ICH Harmonised Tripartite Guideline. ICH E8 General considerations for clinical trials. Geneva: ICH Steering Committee; 1997.

  8. Kimmelman J, London AJ. Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Medicine [Internet]. 2011 [citado 5 Ene 2014];8(3). Disponible en: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.100 1010

  9. Ugalde A, Homedes N. Cuatro palabras sobre ensayos clínicos: ciencia/negocio, riesgo/beneficio. Salud colectiva [Internet]. 2011 [citado 27 Mar 2014];7(2). Disponible en: http://www.scielosp.org/pdf/scol/v7n2/v7n2a02.pdf

  10. Ministerio Salud Pública. Dirección de Ciencia y Técnica. Resolución 10/1992 (1992).

  11. Consejo de Ministros. Ministerio Salud Pública. Resolución 627/1991 (1991).

  12. Ministerio de Ciencia y Tecnología y Medio Ambiente. Resolución 72/2000 (2000).

  13. Los Ensayos Clínicos Multicéntricos. La Organización de los Ensayos Clínicos en Cuba. Libro Resumen del II Taller Internacional de Diseño y Conducción de Ensayos Clínicos. Varadero: CENCEC; 2003.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Méd Electrón. 2014;36